YOLFTbeta
ImageneBio, Inc.

ImageneBio, Inc.

IMA · NASDAQ · Healthcare / Biotechnology

3.47USD+0.02 (+0.58%)

Price History

Full chart

Market Stats

Previous Close3.45
Open3.50
Day Range3.34 – 3.58
52-Week Range3.94 – 9.10
Volume4.02K
Market Cap52.78M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.65
Dividend Yield0.00%
50-Day Avg5.37
200-Day Avg5.89

About

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Kristin Yarema Ph.D.
  • Employees18
  • Headquarters12526 High Bluff Drive, San Diego, CA, United States, 92130, USA
  • Websitehttps://www.inmagenebio.com

Leadership

  • Dr. Kristin Yarema Ph.D.CEO & Director · b. 1971
  • Ms. Yanina Grant-HuertaCFO, Principal Financial Officer & Principal Accounting Officer · b. 1977
  • Dr. Kurinji Pandiyan Ph.D.Chief Strategy & Operations Officer
  • Ms. Renuka Sivendran Ph.D.Chief Technical Officer
  • Mr. Matt Robbins J.D.General Counsel

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue990.00K13.75M9.19M30.98M15.62M9.16M3.50M800.00K
Growth (%)-+1289.19%-33.15%+237.01%-49.59%-41.35%-61.79%-77.14%
Cost of Revenue38.99M24.94M44.85M47.11M64.32M1.02M1.53M1.03M
Gross Profit-38.00M-11.19M-35.65M-16.12M-48.70M8.14M1.97M-233.00K
Gross Margin-3837.98%-81.33%-387.79%-52.03%-311.84%88.86%56.40%-29.13%
Operating Expense2.90M7.31M8.87M18.02M22.20M83.56M38.97M48.22M
Operating Income-40.89M-18.49M-44.52M-34.14M-70.90M-75.42M-37.00M-48.45M
Operating Margin-4130.71%-134.46%-484.22%-110.18%-453.99%-823.33%-1057.14%-6056.38%
EBITDA-40.44M-18.25M-44.22M-33.57M-68.01M-67.31M-35.03M-44.67M
EBITDA Margin-4085.15%-132.69%-480.95%-108.35%-435.48%-734.80%-1000.83%-5583.25%
Net Income-40.87M-16.82M-44.26M-34.12M-68.77M-68.17M-36.57M-45.35M
Net Income Margin-4127.78%-122.28%-481.36%-110.10%-440.29%-744.17%-1044.80%-5668.63%
R&D38.56M24.94M44.85M47.11M64.32M59.65M32.11M28.52M
R&D as % of Total Revenue3895.35%181.33%487.79%152.03%411.84%651.22%917.40%3565.63%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets20.68M85.97M168.40M247.88M172.26M192.09M141.51M152.98M
Total Liabilities66.52M147.44M269.45M40.00M25.29M22.34M15.58M19.84M
Total Equity-45.84M-61.46M-101.05M207.88M146.97M169.76M125.93M133.14M
Cash18.16M82.08M162.49M232.22M59.92M119.89M39.39M34.97M
Total Debt62.58M78.87M186.00K6.99M5.69M10.74M7.52M9.99M
Net Debt44.42M-82.08M-162.31M-225.23M-54.23M-109.16M-31.87M-24.97M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.61M47.93M-37.83M-60.25M-74.11M-79.74M-46.00M-47.84M
Investing Cash Flow10.97M-316.00K2.92M-1.76M-99.28M64.14M-34.90M-5.81M
Financing Cash Flow-16.32M116.18M131.74M1.09M75.98M6.91M135.47M
Capital Expenditure305.00K316.00K766.00K1.76M1.43M414.00K00
Free Cash Flow-11.91M47.61M-38.59M-62.01M-75.54M-80.16M-46.00M-47.84M
FCF to OCF102.63%99.34%102.03%102.92%101.93%100.52%100.00%100.00%

Earnings

Report DateMar 3, 2021May 13, 2021Aug 12, 2021Nov 10, 2021Mar 17, 2022May 12, 2022Aug 11, 2022Nov 7, 2022Mar 14, 2023May 15, 2023Aug 10, 2023Nov 9, 2023Mar 12, 2024May 13, 2024Aug 9, 2024Nov 7, 2024Mar 6, 2025May 8, 2025Jul 24, 2025Nov 12, 2025Mar 10, 2026May 7, 2026Aug 5, 2026Nov 11, 2026
EPS Estimate0.00-0.87--0.420.07-0.47-0.57-0.48-0.39-0.39-0.44-0.40-0.41-0.33-0.36-0.25-0.21-0.19-0.14-1.00-1.15-0.66-0.90-0.83
EPS Actual-0.15-2.52-1.89-0.400.07-0.47-0.57-0.48-0.39-0.39-0.44-0.40-0.41-0.33-0.28-0.21-0.20-0.17-0.69-2.91-0.62-0.95-0.63-
Surprise--189.22%-4.76%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%22.22%17.61%3.24%11.41%-386.94%-191.00%46.28%-43.94%30.00%-
Timing-------------------Pre-market-After-hoursPre-market-

Key Statistics & Ratios

Market Cap52.78M
Enterprise Value-79.30M
Trailing P/E0.00
Forward P/E0.00
Price / Sales83.32
Price / Book0.39
EPS-4.65
Book Value12.60
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-58.37M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-82.68%
Return on Assets-43.06%
Shares Outstanding11.37M
Shares Float5.83M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
54.50%
Insiders
15.70%
Retail / Other
29.80%

Top Institutional Holders

  • Bvf Inc
    1.11M9.84%
  • Blue Owl Capital Holdings LP
    917.69K8.14%
  • Cable Car Capital LLC
    754.75K6.69%
  • Omega Fund Management LLC
    455.36K4.04%
  • Orbimed Advisors LLC
    378.56K3.36%
  • RTW INVESTMENTS, LLC
    334.44K2.97%
  • Vanguard Capital Management, LLC
    325.15K2.88%
  • Trails Edge Capital Partners, LP
    282.00K2.50%
  • BML Capital Management LLC
    200.73K1.78%
  • BlackRock Inc
    129.21K1.15%
  • Renaissance Technologies Corp
    81.70K0.72%
  • Adage Capital Partners Gp LLC
    66.67K0.59%
  • Geode Capital Management, LLC
    59.93K0.53%
  • Citadel Advisors Llc
    55.61K0.49%
  • NEA Management Company, LLC
    50.01K0.44%
  • HSBC Holdings PLC
    34.88K0.31%
  • Sofinnova Ventures
    31.88K0.28%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    264.77K2.35%
  • Worldwide Healthcare Ord
    135.52K1.20%
  • BSF Systematic US Eq Abs Ret A2 USD
    39.65K0.35%

Stock Splits

  • Jul 28, 20251:12